Short answer
OMEROS CORP (OMER) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $10M with net income of $56M.
Q1 2026 key financials · XBRL
- Revenue
- $10M
- Net income
- $56M
- +267.5% YoY
- Operating margin
- -176.1%
- EPS (diluted)
- $0.62
- +206.9% YoY
Source: XBRL data from the OMEROS CORP (OMER) Q1 2026 10-Q on SEC EDGAR. USD.
OMEROS CORP Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $9.9M, versus $0 in Q1 2025, reflecting initial YARTEMLEA sales
- Gross margin 94.1%, based on $9.9M sales and $0.6M product costs
- Best-performing product YARTEMLEA, generating $9.9M in initial sales
- Cash, equivalents and short-term investments $135.3M; operating cash use $14.5M
- Share repurchases $4.2M for 0.4M shares; Q2 R&D and SG&A expected higher with launch investments
Risk Factors
- New risk: $100.0 million share-repurchase program may increase stock-price volatility
- Program suspension or termination could reduce trading price
- Repurchases may elevate stock price above levels absent the program
- $95.9 million remained available for repurchases as of May 11, 2026
- No new regulatory, legal, operational, or debt risks disclosed beyond 2025 Form 10-K risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMEROS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.